Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 1
1993 1
1994 1
1995 2
1996 2
1997 7
1998 6
1999 4
2000 9
2001 17
2002 15
2003 17
2004 12
2005 6
2006 4
2007 12
2008 8
2009 14
2010 7
2011 11
2012 14
2013 10
2014 6
2015 8
2016 9
2017 3
2018 7
2019 8
2020 5
2021 9
2022 7
2023 5
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

235 results

Results by year

Filters applied: . Clear all
Page 1
Antiphospholipid syndrome.
Sammaritano LR. Sammaritano LR. Best Pract Res Clin Rheumatol. 2020 Feb;34(1):101463. doi: 10.1016/j.berh.2019.101463. Epub 2019 Dec 19. Best Pract Res Clin Rheumatol. 2020. PMID: 31866276 Review.
Antiphospholipid syndrome is an autoimmune systemic disorder characterized by arterial, venous, or small vessel thrombosis and/or recurrent early pregnancy loss, fetal loss, or pregnancy morbidity in the setting of documented persistent antiphospholipid antibodies t …
Antiphospholipid syndrome is an autoimmune systemic disorder characterized by arterial, venous, or small vessel thrombosis and/or recurrent …
Deep vein thrombosis: update on diagnosis and management.
Kruger PC, Eikelboom JW, Douketis JD, Hankey GJ. Kruger PC, et al. Med J Aust. 2019 Jun;210(11):516-524. doi: 10.5694/mja2.50201. Epub 2019 Jun 2. Med J Aust. 2019. PMID: 31155730 Review.
Anticoagulation may consist of a parenteral anticoagulant overlapped by warfarin or followed by a direct oral anticoagulant (DOAC) (dabigatran or edoxaban), or of a DOAC (apixaban or rivaroxaban) without initial parenteral therapy. ...Recent evidence s …
Anticoagulation may consist of a parenteral anticoagulant overlapped by warfarin or followed by a direct oral antico …
Monitoring of anticoagulation in thrombotic antiphospholipid syndrome.
Cohen H, Efthymiou M, Devreese KMJ. Cohen H, et al. J Thromb Haemost. 2021 Apr;19(4):892-908. doi: 10.1111/jth.15217. Epub 2021 Feb 20. J Thromb Haemost. 2021. PMID: 33325604 Free article. Review.
Other anticoagulant options include low molecular weight heparin, unfractionated heparin, and fondaparinux. ...In this review, we summarize the tests generally used in monitoring anticoagulant therapy, use of the main anticoagul …
Other anticoagulant options include low molecular weight heparin, unfractionated heparin, and fond …
Low-molecular-weight heparin during pregnancy.
Bazzan M, Donvito V. Bazzan M, et al. Thromb Res. 2001 Jan 1;101(1):V175-86. doi: 10.1016/s0049-3848(00)00403-5. Thromb Res. 2001. PMID: 11342097 Review.
The prevalence of venous thromboembolism (VTE) has been extimated to be 1 per 1000-2000 pregnancies in retrospective studies. Anticoagulant treatment and prophylaxis both before and during pregnancy are based on unfractionated heparin (UH), low- …
The prevalence of venous thromboembolism (VTE) has been extimated to be 1 per 1000-2000 pregnancies in retrospective studies. Anti …
Thromboembolism.
McManus RJ, Fitzmaurice DA, Murray E, Taylor C. McManus RJ, et al. BMJ Clin Evid. 2011 Mar 8;2011:0208. BMJ Clin Evid. 2011. PMID: 21385473 Free PMC article. Review.
Risk factors for DVT include immobility, surgery (particularly orthopaedic), malignancy, pregnancy, older age, and inherited or acquired prothrombotic clotting disorders. ...CONCLUSIONS: In this systematic review we present information relating to the effectiveness and saf …
Risk factors for DVT include immobility, surgery (particularly orthopaedic), malignancy, pregnancy, older age, and inherited or acqui …
Low molecular weight heparin and warfarin in the treatment of patients with antiphospholipid syndrome during pregnancy.
Pauzner R, Dulitzki M, Langevitz P, Livneh A, Kenett R, Many A. Pauzner R, et al. Thromb Haemost. 2001 Dec;86(6):1379-84. Thromb Haemost. 2001. PMID: 11776303 Clinical Trial.
These were treated with s.c. enoxaparin and low dose aspirin. In fourteen pregnancies warfarin was prescribed between weeks 15-34 (warfarin group). ...There was no significant difference in week of delivery, birth weight, or incidence of thrombo …
These were treated with s.c. enoxaparin and low dose aspirin. In fourteen pregnancies warfarin was prescribed between w …
Exploring the role of low-molecular-weight heparins in pregnancy.
Greer IA. Greer IA. Semin Thromb Hemost. 2002 Aug;28 Suppl 3:25-31. doi: 10.1055/s-2002-34072. Semin Thromb Hemost. 2002. PMID: 12232820 Review.
Optimal management of thromboembolic disease, both to prevent VTE and to avoid recurrence of pregnancy complications such as miscarriage, centers on the use of low-molecular-weight heparin (LMWH). ...However, many unanswered questions remain, in …
Optimal management of thromboembolic disease, both to prevent VTE and to avoid recurrence of pregnancy complications such as miscarri …
Anticoagulation therapy.
Ginsberg JA, Crowther MA, White RH, Ortel TL. Ginsberg JA, et al. Hematology Am Soc Hematol Educ Program. 2001:339-57. doi: 10.1182/asheducation-2001.1.339. Hematology Am Soc Hematol Educ Program. 2001. PMID: 11722992 Review.
Despite refinements and standardization in the use of anticoagulants, many problems remain for clinicians. Dr. Crowther describes appropriate starting and maintenance doses of warfarin, factors accounting for inter- and intra-observer variability and importantly, th …
Despite refinements and standardization in the use of anticoagulants, many problems remain for clinicians. Dr. Crowther describes app …
Pregnancy and thrombophilia.
Patnaik MM, Haddad T, Morton CT. Patnaik MM, et al. Expert Rev Cardiovasc Ther. 2007 Jul;5(4):753-65. doi: 10.1586/14779072.5.4.753. Expert Rev Cardiovasc Ther. 2007. PMID: 17605653 Review.
These adverse pregnancy outcomes include recurrent pregnancy losses, intrauterine fetal death, intrauterine growth retardation, preeclampsia and placental abruption. ...Heparin and low-molecular-weight heparins are the anticoagulant …
These adverse pregnancy outcomes include recurrent pregnancy losses, intrauterine fetal death, intrauterine growth retardation …
Valvular Heart Disease and Pregnancy.
Lau ES, Scott NS. Lau ES, et al. Curr Treat Options Cardiovasc Med. 2018 Apr 26;20(6):46. doi: 10.1007/s11936-018-0643-x. Curr Treat Options Cardiovasc Med. 2018. PMID: 29696409 Review.
Maternal mortality and complications are lowest with warfarin use throughout pregnancy; however, fetal outcomes are best with low molecular weight heparin use. ...In addition, it is unclear if better monitoring of low molecular …
Maternal mortality and complications are lowest with warfarin use throughout pregnancy; however, fetal outcomes are best with …
235 results